1
|
Abstract
The immunostimulating complex or 'iscom' was first described 20 years ago as an antigen delivery system with powerful immunostimulating activity. Iscoms are cage-like structures, typically 40 nm in diameter, that are comprised of antigen, cholesterol, phospholipid and saponin. ISCOM-based vaccines have been shown to promote both antibody and cellular immune responses in a variety of experimental animal models. This review focuses on the evaluation of ISCOM-based vaccines in animals over the past 10 years, as well as examining the progress that has been achieved in the development of human vaccines based on ISCOM adjuvant technology.
Collapse
Affiliation(s)
- Megan T Sanders
- Department of Microbiology and Immunology, The University of Melbourne, Australia
| | | | | | | |
Collapse
|
2
|
Abstract
Co-evolving mechanisms of immune clearance and of immune suppression are among the hallmarks of measles. B cells are major targets cells of measles virus (MV) infection. Virus interactions with B cells result both in immune suppression and a vigorous antibody response. Although antibodies fully protect against (re)infection, their importance during the disease and in the presence of a potent cellular response is less well understood. Specific serum IgM appears with onset of rash and confirms clinical diagnosis. After isotype switching, IgG1 develops and confers life-long protection. The most abundant antibodies are specific for the nucleoprotein, but neutralizing and protective antibodies are solely directed against the two surface glycoproteins, the hemagglutinin and the fusion protein. Major neutralizing epitopes have been mapped mainly on the hemagglutinin protein with monoclonal antibodies, producing an increasingly comprehensive map of functional domains.
Collapse
Affiliation(s)
- Fabienne B Bouche
- Department of Immunology and WHO Collaborating Center for Measles, Laboratoire National de Santé, Luxembourg, Luxembourg
| | | | | |
Collapse
|
3
|
Stittelaar KJ, Hoogerhout P, Ovaa W, van Binnendijk RR, Poelen MC, Roholl P, van Els CA, Osterhaus AD, Wiertz EJ. In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine 2001; 20:249-61. [PMID: 11567771 DOI: 10.1016/s0264-410x(01)00265-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Lipopeptidic formulations have been described as efficient activators of cytotoxic T lymphocytes (CTL). To better understand the pathway via which lipopeptides reach the MHC class I molecules we studied the intracellular processing and presentation of a measles virus-derived CTL epitope, to which a palmitoyl moiety was added synthetically. The palmitoyl group was conjugated to the N-terminus either directly or via a spacer sequence. The use of single or double fluorescent-labeled lipopeptides allowed the visualization of intracellular processing of these antigens using confocal microscopy. Our data indicate that the spacer composition influences internalization of the conjugate into the cell, proteasomal degradation, translocation into the ER by the transporter associated with antigen processing (TAP), and the intracellular trafficking of lipopeptides.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 2
- ATP Binding Cassette Transporter, Subfamily B, Member 3
- ATP-Binding Cassette Transporters/genetics
- ATP-Binding Cassette Transporters/metabolism
- Antigen Presentation
- Brefeldin A/pharmacology
- Cell Line, Transformed/immunology
- Cells, Cultured/immunology
- Cysteine Endopeptidases/metabolism
- Endoplasmic Reticulum/metabolism
- Epitopes/chemistry
- Epitopes/immunology
- Golgi Apparatus/metabolism
- HLA Antigens/immunology
- Humans
- Lipoproteins/immunology
- Lipoproteins/metabolism
- Lymphocyte Activation
- Measles virus/immunology
- Micelles
- Microscopy, Confocal
- Microscopy, Fluorescence
- Multienzyme Complexes/metabolism
- Palmitic Acid/chemistry
- Peptide Fragments/chemistry
- Peptide Fragments/immunology
- Proteasome Endopeptidase Complex
- Protein Transport/drug effects
- T-Lymphocytes, Cytotoxic/immunology
- Tumor Cells, Cultured/drug effects
- Tumor Cells, Cultured/immunology
- Tumor Necrosis Factor-alpha/pharmacology
- U937 Cells/metabolism
- Viral Fusion Proteins/chemistry
- Viral Fusion Proteins/immunology
Collapse
Affiliation(s)
- K J Stittelaar
- Laboratory for Vaccine Research, National Institute of Public Health and the Environment, 3720 BA, Bilthoven, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Abstract
The iscom is a uniform stable complex consisting of cholesterol, phospholipid, adjuvant-active saponin, and antigen. The iscom matrix is a particulate complex with identical composition, shape, and morphology, but lacking the incorporated antigen. The assembly of the complex is based on hydrophobic interactions, but antigens that are not hydrophobic can be conjugated with a hydrophobic tail or hidden hydrophobic regions can be exposed, e.g., by acid treatment, to facilitate the incorporation into iscoms. The functional aspects of iscoms are described emphasizing immunomodulation in mouse models. Iscoms prominently enhance the antigen targeting, uptake, and activity of antigen presenting cells including dendritic and B cells and macrophages resulting in the production of proinflammatory cytokines, above all interleukin (IL)-1, IL-6, and IL-12. The expression of costimulatory molecules major histocompatibility complex (MHC) class II, B7.1 and B7.2, is also enhanced. The latter partly explains why the iscom is an efficient adjuvant for elderly mice. Iscoms enhance the Th1 type of response with increased production of IL-2 and interferon gamma. However, with some antigens and particularly in monkeys immunized with HIV iscoms, the production of IL-4 was enhanced. IL-4, IL-2, and interferon gamma (IFNgamma) together with the beta chemokines MIP-1alpha and MIP-1beta correlated with protection against challenge infection with a chimeric virus (simian immunodeficiency virus-human immunodeficiency virus). Iscoms were also shown to induce a potent immune response in the newborn and to be an efficient delivery system for mucosal administration. Technical information is given about formulation of iscoms and about handling of antigens to optimize their incorporation into iscoms.
Collapse
Affiliation(s)
- B Morein
- Department of Veterinary Microbiology, Swedish University of Agricultural Sciences, Uppsala, Sweden.
| | | |
Collapse
|
5
|
6 Preparation and Use of Adjuvants. METHODS IN MICROBIOLOGY 1998. [DOI: 10.1016/s0580-9517(08)70690-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
6
|
Abstract
A little over a decade ago, novel immunostimulating complexes (ISCOMs) were described. This review examines the position and progress that ISCOM technology has achieved in the fields of vaccine research and medicine over this period. Much of the work on ISCOMs has remained in the area of vaccine research where there is still an urgent need for improved adjuvants to help combat important diseases such as AIDS, malaria and influenza. Currently the only widely licensed adjuvants for human use are the aluminium salts, but with the trend towards highly purified subunit vaccines, which are inherently less immunogenic than some of the older vaccines, potent adjuvants capable of promoting specific immune responses are required. ISCOMs are one such technology that offers many of these requirements and as their use in vaccines enters its second decade clinical trials are commencing that will establish whether these submicron, non-living particles composed of saponin, cholesterol, phospholipid and in many cases protein, are useful components for a range of human vaccines.
Collapse
Affiliation(s)
- I G Barr
- CSL Limited, Parkville, Victoria, Australia
| | | |
Collapse
|
7
|
Kersten GF, Crommelin DJ. Liposomes and ISCOMS as vaccine formulations. BIOCHIMICA ET BIOPHYSICA ACTA 1995; 1241:117-38. [PMID: 7640293 DOI: 10.1016/0304-4157(95)00002-9] [Citation(s) in RCA: 95] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- G F Kersten
- Institute of Public Health and Environmental Protection, Department of Product and Process Development, Bilthoven, The Netherlands
| | | |
Collapse
|
8
|
Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, Suhrbier A. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol 1995; 69:1306-9. [PMID: 7815511 PMCID: PMC188710 DOI: 10.1128/jvi.69.2.1306-1309.1995] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The use of synthetic peptides representing cytotoxic T-cell (CTL) epitopes for human vaccination requires the identification of a suitable adjuvant formulation. A single immunization with Montanide ISA720/tetanus toxoid/YPHFMPTNL protected mice against murine cytomegalovirus and induced epitope-specific CTL. Such formulations will find application in peptide-based CTL anti-viral vaccines.
Collapse
Affiliation(s)
- A A Scalzo
- Department of Microbiology, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands
| | | | | | | | | | | |
Collapse
|
9
|
Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 1995; 13:1460-7. [PMID: 8578827 DOI: 10.1016/0264-410x(95)00029-z] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Synthetic peptides can be tailor-made to include any B or T epitopes desired from a single or multiple antigens or organisms. However, peptides in general are not very immunogenic and have not proven easy to incorporate into immunogenic vaccines. ISCOMs is an adjuvant system that has the capability not only to enhance the humoral immunogenicity of a protein but has also been shown to induce cell-mediated immune responses in animals. Synthetic peptide ISCOM vaccines are few because of the difficulty in incorporation of these peptides into ISCOMs. We have shown in this study that non-immunogenic peptides could be made immunogenic by polymerisation, and these polymers could be incorporated into ISCOMs to give highly immunogenic vaccines. Synthetic 20mer peptides containing known B and T-helper epitopes from the E7 protein of the cervical cancer associated human papillomavirus type 16 (HPV16 E7) have been used here as model immunogens. We have compared the humoral immunity induced by these peptides as polymers or as copolymers with a lipid binding 20mer peptide (LAP 20), with or without incorporation into ISCOMs. Unpolymerised peptide elicited no measurable antibody. When polymerised peptide was administered with CFA, or in phosphate-buffered saline (PBS) without adjuvant, or incorporated into ISCOMs, antibodies recognising both the immunising peptide and HPV16 E7 protein were produced. For equal quantities of administered peptide (5 micrograms), ISCOMs gave higher titres of antibody than CFA or PBS. Polymerised peptides induced high antigen-specific IgG2a:IgG1 ratios, which increased with multiple immunisations. These data indicate that polymerised peptides could be incorporated into ISCOMs to form efficient immunogens which may elicit a Th1 type response.
Collapse
Affiliation(s)
- G J Fernando
- Papillomavirus Research Unit, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
| | | | | | | | | | | |
Collapse
|
10
|
Hu A, Kövamees J, Norrby E. Intracellular processing and antigenic maturation of measles virus hemagglutinin protein. Arch Virol 1994; 136:239-53. [PMID: 7518224 DOI: 10.1007/bf01321055] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The intracellular processing and antigenic maturation of the measles virus (MV) hemagglutinin (H) protein in virus infected cells were probed with murine monoclonal antibodies (Mabs) that reacted with continuous and discontinuous epitopes. The antibodies distinguished between the immature, cotranslational monomeric form of the protein and the mature, dimeric hemagglutinin structure. This was evidenced by testing of immunoreactivity of the Mabs with synthetic peptides, by in vitro synthesized H protein analysis, and by pulse-chase analysis of gel separated monomeric and dimeric forms of the H protein. Time kinetics analysis showed that the protein was synthesized as monomers and most of them were converted into dimers with t1/2 about 30 min. The H protein remained endoglycosidase H (Endo H) sensitive up to 30 min and started to acquire partial resistance to Endo H between 30 and 60 min (t1/2 about 60 min) after synthesis. Oligomerization of the H protein was unaffected in virus infected cells treated with a compound (carbonylcyanide m-chlorophenylhydrazone, CCCP) that blocks transport from the endoplasmic reticulum (ER) to the Golgi complex. These results suggest that the H protein dimerization takes place in the ER before its transport to the medial Golgi complex. The Mabs specific for discontinuous epitopes reacted with the H protein in cells treated with CCCP. Thus conformational antigenic epitope formation appears to take place in the ER.
Collapse
Affiliation(s)
- A Hu
- Department of Virology, School of Medicine, Karolinska Institute, Stockholm, Sweden
| | | | | |
Collapse
|
11
|
Obeid OE, Partidos CD, Steward MW. Analysis of the antigenic profile of measles virus haemagglutinin in mice and humans using overlapping synthetic peptides. Virus Res 1994; 32:69-84. [PMID: 7518172 DOI: 10.1016/0168-1702(94)90062-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
In this study, a panel of 55 synthetic peptides representing 92.2% of the haemagglutinin (H) glycoprotein of measles virus (MV) were used to study the antigenic profile of the H molecule of anti-MV antibodies raised in mice and late convalescent human sera. In addition the immunogenicity of these peptides was tested in two mouse strains. Mouse anti-MV antibodies had different fine specificity of binding to the peptides depending on the mouse strain. Thus in BALB/c (H-2d) mice, anti-MV antibodies recognised six peptides representing residues 103-117; 123-137; 242-255; 293-307 and 463-477. In TO (H-2s) mice, anti-MV antibodies recognised peptides representing residues 49-72 and 463-477. When the immunogenicity of the peptides was tested, 29 were immunogenic in BALB/c mice and 34 were immunogenic in TO mice. Several of the anti-peptide antisera were found to cross-react with MV, depending on the solid phase assay system used but none were able to inhibit virus infectivity in vitro. The reactivity of a panel of late convalescent human sera with the peptides was heterogeneous and the extent of the binding to the peptides was related to the titre of anti-MV. However, human sera recognized certain peptides more frequently than others, in particular peptides at the carboxyl-terminus.
Collapse
Affiliation(s)
- O E Obeid
- Department of Clinical Sciences, London School of Hygiene and Tropical Medicine, UK
| | | | | |
Collapse
|
12
|
Muller CP, Schroeder T, Tu R, Brons NH, Jung G, Schneider F, Wiesmüller KH. Analysis of the neutralizing antibody response to the measles virus using synthetic peptides of the haemagglutinin protein. Scand J Immunol 1993; 38:463-71. [PMID: 7694357 DOI: 10.1111/j.1365-3083.1993.tb02589.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Infection or immunization with measles virus induces a protective immune reaction including neutralizing antibodies against the haemagglutinin and fusion protein. The reactivity of the polyclonal IgG response of sera obtained from late convalescent donors was studied, using overlapping 15mer peptides covering the complete sequence of the measles virus haemagglutinin. Most sera reacted with a similar set of peptides generating a characteristic binding pattern. The reactive peptides correspond to a region mediating cell hemolysis (aa310-325), to regions which serve as targets to neutralizing antibodies and to a putative transmembrane region (aa35-58). The latter region contains also a human T-cell epitope providing evidence of a non-random association of T- and B-cell epitopes. We also immunized different strains of mice and rabbits with measles virus. In contrast to the human sera, animal sera with strong neutralizing activities did not react with any of the H-protein peptides. The mostly weak reactivities with the linear sequences contrast with the strong neutralizing activities of the human or animal antibodies, suggesting that these primarily recognize the fusion protein or conformational epitopes of the haemagglutinin protein.
Collapse
Affiliation(s)
- C P Muller
- Laboratoire National de Santé, Luxembourg
| | | | | | | | | | | | | |
Collapse
|